Carol Aghajanian, MD, from the Memorial Sloan-Kettering Cancer Center, discusses the difficulties with a gold standard clinical trial endpoint in ovarian cancer.
More on ovarian cancer: [ Ссылка ]
![](https://i.ytimg.com/vi/K_WvySFx81E/mqdefault.jpg)
Carol Aghajanian, MD, from the Memorial Sloan-Kettering Cancer Center, discusses the difficulties with a gold standard clinical trial endpoint in ovarian cancer.
More on ovarian cancer: [ Ссылка ]